S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Alector Stock Price, News & Analysis (NASDAQ:ALEC)

$6.12
+0.32 (+5.52%)
(As of 12/8/2023 ET)
Compare
Today's Range
$5.65
$6.39
50-Day Range
$3.77
$6.68
52-Week Range
$3.66
$9.86
Volume
668,308 shs
Average Volume
593,985 shs
Market Capitalization
$514.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.70

Alector MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
123.9% Upside
$13.70 Price Target
Short Interest
Bearish
11.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
-0.72mentions of Alector in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$3.19 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.78) to ($2.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

443rd out of 954 stocks

Biological Products, Except Diagnostic Industry

50th out of 128 stocks


ALEC stock logo

About Alector Stock (NASDAQ:ALEC)

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Stock Price History

ALEC Stock News Headlines

These biotechs targeting multiple neurodegenerative diseases (ALEC)
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Alector: Q3 Earnings Snapshot
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
High Tide, Alector among healthcare movers
Analyst Expectations for Alector's Future
Alector (ALEC) Receives a Buy from Mizuho Securities
H.C. Wainwright Sticks to Its Buy Rating for Alector (ALEC)
Alector to Host Mid-Year Earnings Conference Call
See More Headlines
Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALEC
Fax
N/A
Employees
246
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$13.70
High Stock Price Target
$41.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+123.9%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-133,310,000.00
Net Margins
-146.80%
Pretax Margin
-142.37%

Debt

Sales & Book Value

Annual Sales
$96.31 million
Book Value
$2.59 per share

Miscellaneous

Free Float
72,357,000
Market Cap
$514.91 million
Optionable
Not Optionable
Beta
0.69

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Arnon Rosenthal Ph.D. (Age 67)
    Co-Founder, CEO & Director
    Comp: $1.02M
  • Dr. Sara Kenkare-Mitra Ph.D. (Age 55)
    President and Head of Research & Development
    Comp: $1.19M
  • Dr. Marc Grasso M.D. (Age 50)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $738.05k
  • Dr. Gary Romano M.D. (Age 61)
    Ph.D., Chief Medical Officer
    Comp: $602.98k
  • Mr. Peter Heutink Ph.D.
    Chief Scientific Officer
  • Katie Hogan
    Senior Director of Corporate Communication & Investor Relations
  • Ms. Danielle Pasqualone J.D.
    Ph.D., General Counsel
  • Ms. Clare Hunt M.B.A.
    Chief People Officer
  • Ms. Kristina Cutter M.P.H.
    Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
  • Ms. Virginia DeJesus-Rueff M.B.A.
    Chief of Staff & Head of Strategy














ALEC Stock Analysis - Frequently Asked Questions

Should I buy or sell Alector stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares.
View ALEC analyst ratings
or view top-rated stocks.

What is Alector's stock price target for 2024?

9 brokers have issued 1 year price objectives for Alector's stock. Their ALEC share price targets range from $4.00 to $41.00. On average, they anticipate the company's share price to reach $13.70 in the next twelve months. This suggests a possible upside of 123.9% from the stock's current price.
View analysts price targets for ALEC
or view top-rated stocks among Wall Street analysts.

How have ALEC shares performed in 2023?

Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 33.7% and is now trading at $6.12.
View the best growth stocks for 2023 here
.

Are investors shorting Alector?

Alector saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 7,150,000 shares, a decrease of 6.9% from the October 31st total of 7,680,000 shares. Based on an average daily trading volume, of 717,100 shares, the short-interest ratio is currently 10.0 days. Approximately 11.7% of the shares of the stock are sold short.
View Alector's Short Interest
.

When is Alector's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ALEC earnings forecast
.

How were Alector's earnings last quarter?

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.12. The business had revenue of $9.11 million for the quarter, compared to analysts' expectations of $9 million. Alector had a negative net margin of 146.80% and a negative trailing twelve-month return on equity of 74.78%.

What ETF holds Alector's stock ?

iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

What is Arnon Rosenthal's approval rating as Alector's CEO?

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

When did Alector IPO?

(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Who are Alector's major shareholders?

Alector's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.47%), Braidwell LP (4.84%), Morgan Stanley (3.97%), JPMorgan Chase & Co. (2.72%), Euclidean Capital LLC (1.55%) and Jacobs Levy Equity Management Inc. (0.92%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends
.

How do I buy shares of Alector?

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Alector have any subsidiaries?
The following companies are subsidiares of Alector: Alector LLC.
Read More
This page (NASDAQ:ALEC) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -